AgomAb Therapeutics NV (AGMB)

NASDAQ: AGMB · Real-Time Price · USD

8.57

-0.48 (-5.30%)

Oct 26, 2026, 4:00 PM EDT - Market closed

AgomAb Therapeutics NV Earnings Call Transcripts

Fiscal Year 2026

Study result
In the 49-patient STENOVA open-label extension, ontunisertib maintained favorable safety and gut-restricted PK through up to 60 weeks. Exploratory findings included a 3% event rate and 97% clinical remission at week 48, with efficacy interpretation limited by the uncontrolled design.

Read full transcript →

Press release
Slides